Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
9.68
-0.19 (-1.93%)
Jul 15, 2026, 4:00 PM EDT - Market closed
Replimune Group Employees
Replimune Group had 465 employees as of March 31, 2026. The number of employees decreased by 14 or -2.92% compared to the previous year.
Employees
465
Change (1Y)
-14
Growth (1Y)
-2.92%
Revenue / Employee
n/a
Profits / Employee
-$675,140
Market Cap
812.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 465 | -14 | -2.92% |
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| ARS Pharmaceuticals | 159 |
| Aura Biosciences | 113 |
| Odyssey Therapeutics | 100 |
| Theravance Biopharma | 90 |
| CytomX Therapeutics | 69 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
REPL News
- 14 hours ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL) - GlobeNewsWire
- 2 days ago - Replimune Group Proxy statement: Proxy filing - Filings
- 7 days ago - Replimune Group put volume heavy and directionally bearish - TheFly
- 8 days ago - Replimune Group put volume heavy and directionally bearish - TheFly
- 15 days ago - Replimune price target raised to $9 from $6 at Wedbush - TheFly
- 15 days ago - BMO double upgrades Replimune on higher chances of FDA approval - TheFly
- 16 days ago - Replimune Group put volume heavy and directionally bearish - TheFly
- 16 days ago - Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - GlobeNewsWire